Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Relmada Therapeutics, Inc.NASDAQ: RLMD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$19.05M, compared with -$17.56M a year earlier. Trailing-twelve-month EBITDA was -$58.88M.
Context
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +28.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.05M+4.1% QoQ
- Last fiscal yearDec 2025
- -$57.39M+28.3% YoY
- LTMMar 2026
- -$58.88M-297.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.5% | +100.0% | +108.5 pp |
| 1 year | +28.3% | +100.0% | +71.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (57.39M) USD
- Year-over-year change
- +28.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (57.39M) | +28.3% |
| FY2024 | 2024-12-31 | (79.98M) | -1728.9% |
| FY2023 | 2023-12-31 | 4.91M | +103.1% |
| FY2022 | 2022-12-31 | (157.04M) | -24.9% |
| FY2021 | 2021-12-31 | (125.75M) | — |
EBITDA vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's LTM Mar 2026 EBITDA of -$58.88M is the 3rd highest of the 9 companies compared; the peer median is -$80.14M.
- Its year-over-year change of -297.6% is the lowest of 9, against a peer median of +6.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M | +264.5% | — | 223.7% | |
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$62.31M | +76.4% | — | 1453.8% |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$102.73M | +7.3% | — | — | |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding RLMD) | -$80.14M | +6.0% | — | 761.2% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 90.62M | 113.32M | 54.81M | 46.18M | 744.56K |
| Selling, General & Admin | 35.08M | 47.93M | 48.9M | 37.72M | 311.9K |
| Operating Expenses | 125.7M | 161.25M | 103.7M | 83.89M | 59.1M |
| Depreciation & Amortization | 1.26K | 2K | 103.7M | 0 | 0 |
| EBITDA | (125.75M) | (157.04M) | 4.91M | (79.98M) | (57.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (125.7M) | (161.25M) | (103.7M) | (83.89M) | (59.1M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 1.2M | 2.66M | 5.15M | 3.53M | 1.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (48.32K) | 4.21M | 4.91M | 3.91M | 1.72M |
| Income Before Tax | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| EPS (Diluted) | (7.16) | (5.30) | (3.28) | (2.65) | (1.45) |
| Weighted Avg Shares | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
| Weighted Avg Shares (Diluted) | 17.55M | 29.63M | 30.1M | 30.16M | 39.48M |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.